Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Intestinal Microbiota in … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Intestinal Microbiota in Cardiovascular Health and Disease

Artikel i vetenskaplig tidskrift
Författare W. H. W. Tang
Fredrik Bäckhed
U. Landmesser
S. L. Hazen
Publicerad i Journal of the American College of Cardiology
Volym 73
Nummer/häfte 16
Sidor 2089-2105
ISSN 0735-1097
Publiceringsår 2019
Publicerad vid Institutionen för medicin, avdelningen för molekylär och klinisk medicin
Sidor 2089-2105
Språk en
Länkar dx.doi.org/10.1016/j.jacc.2019.03.0...
Ämnesord dysbiosis, intestinal microbiota, secondary bile acids, short-chain fatty acid, trimethylamine N-oxide, trimethylamine-n-oxide, coronary-artery-disease, gut microbiota, heart-failure, l-carnitine, blood-pressure, myocardial-infarction, wide, association, fish consumption, prognostic value, Cardiovascular System & Cardiology
Ämneskategorier Kardiologi

Sammanfattning

Despite major strides in reducing cardiovascular disease (CVD) burden with modification of classic CVD risk factors, significant residual risks remain. Recent discoveries that linked intestinal microbiota and CVD have broadened our understanding of how dietary nutrients may affect cardiovascular health and disease. Although next-generation sequencing techniques can identify gut microbial community participants and provide insights into microbial composition shifts in response to physiological responses and dietary exposures, provisions of prebiotics or probiotics have yet to show therapeutic benefit for CVD. Our evolving understanding of intestinal microbiota-derived physiological modulators (e.g., short-chain fatty acids) and pathogenic mediators (e.g., trimethylamine N-oxide) of host disease susceptibility have created novel potential therapeutic opportunities for improved cardiovascular health. This review discusses the roles of human intestinal microbiota in normal physiology, their associations with CVD susceptibilities, and the potential of modulating intestinal microbiota composition and metabolism as a novel therapeutic target for CVD. (C) 2019 by the American College of Cardiology Foundation.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?